| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.23313 |
| P698 | PubMed publication ID | 18224661 |
| P50 | author | Alex A Adjei | Q107055463 |
| Donald W Northfelt | Q116795045 | ||
| P2093 | author name string | Marie-Christine Aubry | |
| Jeff A Sloan | |||
| Daniel A Nikcevich | |||
| Kendrith M Rowland | |||
| North Central Cancer Treatment Group | |||
| Scott H Okuno | |||
| Nathan R Foster | |||
| Matthew J Maurer | |||
| Gamini S Soori | |||
| Robert Delaune | |||
| Carl G Kardinal | |||
| P2860 | cites work | Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee. | Q37697055 |
| Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma | Q45216736 | ||
| A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma | Q46590810 | ||
| Surgically debulked malignant pleural mesothelioma: results and prognostic factors. | Q50956871 | ||
| Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. | Q51260397 | ||
| An analysis of variance test for normality (complete samples) | Q57253423 | ||
| Use of a modified symptom distress scale in assessment of the cancer patient | Q69588308 | ||
| Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma | Q72387721 | ||
| Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer | Q77562069 | ||
| The European mesothelioma epidemic | Q24650064 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma | Q32161570 | ||
| A three-outcome design for phase II clinical trials. | Q33181907 | ||
| Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Q33329809 | ||
| Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study | Q33331901 | ||
| Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study | Q33504586 | ||
| Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | Q34485292 | ||
| Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine | Q34523011 | ||
| Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary | Q36097491 | ||
| The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. | Q36617025 | ||
| Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma | Q36643866 | ||
| A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. | Q36646087 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1772-1779 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. | |
| P478 | volume | 112 |
| Q37090808 | Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future |
| Q38909086 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. |
| Q64285361 | Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial |
| Q93338919 | Product review: avelumab, an anti-PD-L1 antibody |
| Q34622818 | Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q36311501 | The Complementary Nature of Patient-Reported Outcomes and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591). |
| Q36119749 | The Globalization of Cooperative Groups |
| Q59132459 | The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey |
| Q38758684 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials |
Search more.